HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Validation of p16INK4a as a marker of oncogenic human papillomavirus infection in cervical biopsies from a population-based cohort in Costa Rica.

Abstract
Due to the high prevalence of cancer-associated types of human papillomavirus (HPV) and the poorly reproducible histologic classification of low-grade lesions, identifying infected women at highest risk for cancer prior to neoplastic progression remains a challenge. We therefore explored the utility of p16INK4a immunostaining as a potential diagnostic and prognostic biomarker for cervical neoplasia using paraffin-embedded tissue blocks (punch biopsies and loop electrosurgical excision procedures) obtained from women referred to colposcopy during the enrollment phase of the Guanacaste Project (1993 to 1994). All blocks from 292 women selected by HPV status (HPV negative, nononcogenic HPV positive, or oncogenic HPV positive) and representing the diagnostic spectrum of the population [normal to precancer: cervical intraepithelial neoplasia (CIN) 3] were immunostained for p16INK4a using the p16INK4a research kit based on the monoclonal antibody clone E6H4 (MTM Laboratories, Heidelberg, Germany). For CIN3, the sensitivity of diffuse p16INK4a immunostaining was 100% and the specificity was 95%. For CIN2, the sensitivity and specificity for diffuse staining were 81.1% and 95.4%, respectively. Generalized to the 10,000-woman cohort, this translated to positive predictive value and negative predictive value of 13.9% and 100% for CIN3, respectively, and 20.4% and 99.7% for CIN2 or CIN3, respectively. Of women with an initial diagnosis of less than CIN2 for whom follow-up data for up to 5 to 7 years were available, 44% with diffuse staining developed persistent infection (CIN2 or CIN3). Whereas our data support the diagnostic potential for p16INK4a, further prospective studies with detailed follow-up determining the prognostic capacity of this marker are needed.
AuthorsSophia S Wang, Marcus Trunk, Mark Schiffman, Rolando Herrero, Mark E Sherman, Robert D Burk, Allan Hildesheim, M Concepcion Bratti, Tom Wright, Ana Cecilia Rodriguez, Sabrina Chen, Anja Reichert, Christina von Knebel Doeberitz, Ruediger Ridder, Magnus von Knebel Doeberitz
JournalCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology (Cancer Epidemiol Biomarkers Prev) Vol. 13 Issue 8 Pg. 1355-60 (Aug 2004) ISSN: 1055-9965 [Print] United States
PMID15298958 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Validation Study)
Chemical References
  • Biomarkers, Tumor
  • DNA, Viral
  • Indicators and Reagents
Topics
  • Adolescent
  • Adult
  • Biomarkers, Tumor (analysis)
  • Case-Control Studies
  • Cervix Uteri (pathology, virology)
  • Cohort Studies
  • Colposcopy (methods)
  • Costa Rica (epidemiology)
  • DNA, Viral (analysis)
  • Female
  • Humans
  • Immunohistochemistry
  • Incidence
  • Indicators and Reagents
  • Middle Aged
  • Papillomaviridae (isolation & purification)
  • Papillomavirus Infections (diagnosis, epidemiology)
  • Risk Assessment
  • Sensitivity and Specificity
  • Uterine Cervical Neoplasms (epidemiology, pathology, virology)
  • Vaginal Smears
  • Uterine Cervical Dysplasia (epidemiology, pathology, virology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: